Clinical Trial Update: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates the combination of obinutuzumab with lenalidomide for relapsed/refractory follicular and aggressive B-cell lymphomas, spanning Phase 1 an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Follicular Lymphoma Patients (Phase IB), Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) | Phase 1, Phase 2 | Status: COMPLETED